MedTrace Logo

Study of LM-302 in Patients With Advance Solid Tumors

NCT05161390 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2025-09-12

No results posted yet for this study

Summary

A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

LM-302 Injection

LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.

Sponsors & Collaborators

  • LaNova Medicines Zhejiang Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jin Li · Shanghai East Hospital

  • Wei Shen · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  • Yuping Sun · Shandong Province Cancer Hospital

  • Yanqiao Zhang · The Second Affiliated Hospital of Harbin Medical University

  • Jianping Xiong · The First Affiliated Hospital of Nanchang University

  • Wenhui Lou · Shanghai Zhongshan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-26
Primary Completion
2025-01-10
Completion
2025-01-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05161390 on ClinicalTrials.gov